<SEC-DOCUMENT>0001104659-20-084390.txt : 20200717
<SEC-HEADER>0001104659-20-084390.hdr.sgml : 20200717
<ACCEPTANCE-DATETIME>20200717123718
ACCESSION NUMBER:		0001104659-20-084390
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200717
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200717
DATE AS OF CHANGE:		20200717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				131840497
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36410
		FILM NUMBER:		201033249

	BUSINESS ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2025059d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
<B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
July 17, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(EXACT NAME OF REGISTRANT AS SPECIFIED IN
CHARTER)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-left: 5.4pt"><U>Delaware</U></TD><TD STYLE="padding-bottom: 1pt; width: 2%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-left: 5.4pt"><U>01-36410</U></TD><TD STYLE="padding-bottom: 1pt; width: 2%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-left: 5.4pt"><U>13-1840497</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-left: 5.4pt">(State or other jurisdiction of incorporation)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-left: 5.4pt">(Commission File Number)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-left: 5.4pt">(IRS Employer Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Glenpointe Centre East, 3rd Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>300 Frank W. Burr Boulevard, Suite 21</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Teaneck, New Jersey 07666-6712</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of Principal Executive Offices,
including Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(201) 329-7300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Title of each class</U></B></FONT></TD>
    <TD STYLE="width: 24%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Trading Symbol(s)</U></B></FONT></TD>
    <TD STYLE="width: 37%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Name of each exchange on which registered</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class A Common Stock, $0.0001 par value per share</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>PAHC</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>NASDAQ Stock Market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01. Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 17, 2020, Phibro Animal Health
Corporation (the &ldquo;Company&rdquo;) issued a press release regarding the Food and Drug Administration&rsquo;s intention to
take a number of actions related to its ongoing review of the regulatory status of Mecadox&reg; and reiterating the safety of Mecadox
when used in accordance with its label. The most recent 12 month sales (through June 30, 2020) for Mecadox were approximately $17
million. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in the press
release is being furnished and shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of, or otherwise regarded
as filed under, the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d) &nbsp;Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; width: 88%; text-align: left"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="tm2025059d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm2025059d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release, dated July 17, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Date: July 17, 2020</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">PHIBRO ANIMAL HEALTH CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 43%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas G. Dagger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;<BR>
Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Thomas G. Dagger<BR>
Senior Vice President, General Counsel <BR>
and Corporate Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2025059d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="image_004.jpg" ALT=""></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phibro Animal Health Corporation Reiterates
Safety of Mecadox&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TEANECK, NJ, July 17, 2020 (Business Wire) -- (NASDAQ:PAHC)
Today, the Food and Drug Administration (FDA) provided notice of Federal Register publication of its intention to take a number
of actions related to its ongoing review of the regulatory status of Mecadox&reg; (carbadox). Mecadox has been approved and sold
in the United States for more than 45 years and is a widely used treatment for controlling bacterial diseases in swine, including
Salmonella and swine dysentery, resulting in improved health and welfare for newly born and young pigs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2016, the FDA issued a Notice of Opportunity for Hearing
(NOOH) setting in motion the initial steps in a process to rescind its approval of carbadox based on concerns about the persistence
of carcinogenic residues. Phibro requested a hearing, and over the next four years continued an ongoing process of responding collaboratively
and transparently to FDA&rsquo;s Center for Veterinary Medicine (CVM) inquiries to provide extensive and meticulous research and
data that confirm the safety of carbadox.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro believes that the evidence submitted to FDA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Concludes that no carbadox residues of carcinogenic concern can be detected at the end of the labeled withdrawal period.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Confirms that carbadox remains a safe drug to control bacterial diseases in swine.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Increases our collective understanding of the drug&rsquo;s metabolism, residue characterization and depletion.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Reinforces and affirms prior FDA determinations that the use of carbadox is safe as approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the notice published by the FDA, the agency states it
does not agree with Phibro&rsquo;s scientific conclusions and announced a new process for the review of carbadox, instead of
following its own procedure and moving forward with a hearing that would resolve the parties&rsquo; differing interpretations
of the science supporting the safety of carbadox. Phibro disagrees with the agency&rsquo;s conclusions and is disappointed
that it is taking these steps. Phibro stands ready to discuss alternative regulatory methods if the FDA believes that the
current method is inappropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro has requested to the FDA Office of the Commissioner that the agency continue the process it started in 2016 and proceed
with a hearing to review the substantial body of data supporting the safety of carbadox. In addition to the science proving the
safety of carbadox, Phibro believes the unparalleled therapeutic efficacy, which has significant animal health and welfare implications,
supports the continued use of carbadox.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro will continue to defend swine producers&rsquo; ability
to use Mecadox to protect the health and welfare of their animals. Mecadox continues to be available for use by swine producers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phibro Animal Health Corporation is a diversified
global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping
veterinarians and farmers produce healthy, affordable food while using fewer natural resources. For further information, please
visit www.pahc.com.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Richard Johnson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer, Phibro Animal
Health Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 201-329-7300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>investor.relations@pahc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 -(# 2(  A$! Q$!_\0
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MF*UB$:%MQ )Z_C]*Z,-@ITJBG)K0TI4'&5V6****](Z@HHHH **** "BBB@
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M.T?Q?>:GJD%H;:%1(>2 <@ 9/?VJY)XO2#4VLY["1%_M!;!)1*I#.5W[L=0
MI!/UQ10FJZ;IZV-HU(R5T=+17F\OQAT])G6/1]0E16(610N&'8CZT5U_5*W\
MOY?YCYXE:/0I5;3_ !*=3N6N[G4)+B2%O]2#M<#"]<@ #.3Q58>%TLY-/N8+
MHHT>@/P$X,FQU\SKUQ(?RHHKH527YD61H6_@2RU&2:6ZN)&%@+:.-0N T<<
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L[D^U%%?099)QHW7<[L.ER&;_ ,(# XW-><MR<0X'_H5%%%>G[>IW->5'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
